YM-264 fumarate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526945

CAS#: 131888-54-5 (fumarate)

Description: YM-264 is a selective, potent and orally active platelet-activating factor antagonist potentially for the treatment of asthma. YM264 inhibited [3H] platelet-activating factor binding to rabbit platelet membranes with a pKi value of 8.85. YM264 inhibited the platelet-activating factor-induced human, rabbit and guinea-pig platelet aggregation with pA2 values of 8.68, 8.33 and 8.14, respectively. ight in a parallel manner.

Chemical Structure

YM-264 fumarate
CAS# 131888-54-5 (fumarate)

Theoretical Analysis

MedKoo Cat#: 526945
Name: YM-264 fumarate
CAS#: 131888-54-5 (fumarate)
Chemical Formula: C28H36N4O5S
Exact Mass:
Molecular Weight: 540.679
Elemental Analysis: C, 62.20; H, 6.71; N, 10.36; O, 14.80; S, 5.93

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 126911-71-5 (free base)   131888-54-5 (fumarate)    

Synonym: YM-264; YM 264; YM-64.

IUPAC/Chemical Name: (4-(3-methyl-3-phenylbutyl)piperazin-1-yl)(2-(pyridin-3-yl)thiazolidin-4-yl)methanone fumarate


InChi Code: InChI=1S/C24H32N4OS.C4H4O4/c1-24(2,20-8-4-3-5-9-20)10-12-27-13-15-28(16-14-27)23(29)21-18-30-22(26-21)19-7-6-11-25-17-19;5-3(6)1-2-4(7)8/h3-9,11,17,21-22,26H,10,12-16,18H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 540.679 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Tsukumo Y, Harada D, Manabe H. Pharmacological characterization of itch-associated response induced by repeated application of oxazolone in mice. J Pharmacol Sci. 2010;113(3):255-62. PubMed PMID: 20595784.

2: Suzuki T, Nagaoka H, Hara H, Takeuchi M, Saito M, Yamada T, Tomioka K, Matsumoto H, Takanuki K, Mase T. 2-(3-Pyridyl)thiazolidine-4-carboxamide derivatives. III.) Synthesis of metabolites and metabolism of 2-(3-pyridyl)thiazolidine-4-carboxamides YM461 and YM264 as platelet-activating factor (PAF) receptor antagonists. Chem Pharm Bull (Tokyo). 1999 Feb;47(2):165-70. PubMed PMID: 10071851.

3: Yamano M, Umeda M, Miyata K, Yamada T. Protective effects of a PAF receptor antagonist and a neutrophil elastase inhibitor on multiple organ failure induced by cerulein plus lipopolysaccharide in rats. Naunyn Schmiedebergs Arch Pharmacol. 1998 Aug;358(2):253-63. PubMed PMID: 9750012.

4: Nagaoka H, Hara H, Suzuki T, Takahashi T, Takeuchi M, Matsuhisa A, Saito M, Yamada T, Tomioka K, Mase T. 2-(3-Pyridyl)thiazolidine-4-carboxamides. 1. Novel orally active antagonists of platelet-activating factor (PAF). Chem Pharm Bull (Tokyo). 1997 Oct;45(10):1659-64. PubMed PMID: 9353894.

5: Arima M, Yukawa T, Makino S. Effect of YM264 on the airway hyperresponsiveness and the late asthmatic response in a guinea pig model of asthma. Chest. 1995 Aug;108(2):529-34. PubMed PMID: 7634894.

6: Yamada T, Tomioka K, Horie M, Sakurai Y, Nagaoka H, Mase T. Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem Biophys Res Commun. 1991 Apr 30;176(2):781-5. PubMed PMID: 2025290.

7: Yamada T, Tomioka K, Saito M, Horie M, Mase T, Hara H, Nagaoka H. Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor. Arch Int Pharmacodyn Ther. 1990 Nov-Dec;308:123-36. PubMed PMID: 2099131.

Additional Information